Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2013 - 2014)

Ultragenyx Pharmaceutical's (RARE) quarterly Gains from Investment Securities came in at $3.3 million in Q1 2014, up 166300.0% year-on-year from N/an in Q1 2013, and up 82.34% on a QoQ basis from $1.8 million in Q4 2013.

Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2013 - 2014) Analysis & Trends

Ultragenyx Pharmaceutical (RARE) has 2 years of Gains from Investment Securities data on file, last reported at $3.3 million in Q1 2014.

  • On a quarterly basis, Gains from Investment Securities rose 166300.0% year-over-year to $3.3 million in Q1 2014; TTM through Dec 2014 was $3.3 million, a 14.58% increase from a year earlier, with the FY2014 full-year figure at $3.3 million, up 14.58% from the prior year.
  • Gains from Investment Securities for Q1 2014 stood at $3.3 million, up from $1.8 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for RARE reached as high as $3.3 million in Q1 2014 and fell as low as -$2000.0 in Q1 2013.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2014 3.32 Mn
Mar 31, 2014 3.32 Mn
Dec 31, 2013 1.82 Mn
Dec 31, 2013 1.82 Mn
Sep 30, 2013 706,000.00
Sep 30, 2013 706,000.00
Jun 30, 2013 374,000.00
Jun 30, 2013 374,000.00
Mar 31, 2013 -2,000.00
Mar 31, 2013 -2,000.00